Curis, Inc.
Clinical trials sponsored by Curis, Inc., explained in plain language.
-
New pill combo shows promise for tough brain cancer
Disease control Recruiting nowThis study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with another drug (ibrutinib), in adults with a rare brain lymphoma that has returned or not responded to prior therapy. The goal is to find safe doses and see if the combination can shrink tu…
Phase: PHASE1, PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated May 17, 2026 06:58 UTC
-
New combo aims to deepen remissions in blood cancer patients
Disease control Recruiting nowThis phase 2 study tests whether adding the experimental drug emavusertib to an approved targeted therapy (zanubrutinib) can improve outcomes for adults with chronic lymphocytic leukemia (CLL) and related B-cell cancers. About 108 participants will receive the combination to see …
Phase: PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated May 05, 2026 11:55 UTC